Importantly, Choe et al. reported that treatment with miR-550a-3-5p improved the sensitivity of vemurafenib by inhibiting YAP, and reducing the activity of AKT in vemurafenib-resistant colon cancer and melanoma cells [45]. The gene discussed is YAP1; the disease is colonic neoplasm.